[go: up one dir, main page]

CL2016001367A1 - Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015). - Google Patents

Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015).

Info

Publication number
CL2016001367A1
CL2016001367A1 CL2016001367A CL2016001367A CL2016001367A1 CL 2016001367 A1 CL2016001367 A1 CL 2016001367A1 CL 2016001367 A CL2016001367 A CL 2016001367A CL 2016001367 A CL2016001367 A CL 2016001367A CL 2016001367 A1 CL2016001367 A1 CL 2016001367A1
Authority
CL
Chile
Prior art keywords
wnt
activators
gamma
beta
diketones
Prior art date
Application number
CL2016001367A
Other languages
English (en)
Inventor
John Hood
David Mark Wallace
Charlene Barroga
Kc Sunil Kumar
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of CL2016001367A1 publication Critical patent/CL2016001367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DERIVADOS DE GAMMA-DICETONAS O SUS SALES, COMO ACTIVADORES DE LA RUTA DE SEÑALIZACIÓN DE WNT/BETA-CATENINA; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y SU USO PARA TRATAR UNA ENFERMEDAD NEURODEGENERATIVA, OCULAR, OSTEOPOROSIS, ENFERMEDAD OCULAR, ENTRE OTRAS (DIVISIONAL DE SOLICITUD N° 2363-2015).
CL2016001367A 2013-02-22 2016-06-03 Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015). CL2016001367A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361768033P 2013-02-22 2013-02-22

Publications (1)

Publication Number Publication Date
CL2016001367A1 true CL2016001367A1 (es) 2017-07-14

Family

ID=51388762

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015002363A CL2015002363A1 (es) 2013-02-22 2015-08-21 Gamma-dicetonas como activadores de la ruta de señalizacion de wnt/beta- catenina.
CL2016001367A CL2016001367A1 (es) 2013-02-22 2016-06-03 Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015002363A CL2015002363A1 (es) 2013-02-22 2015-08-21 Gamma-dicetonas como activadores de la ruta de señalizacion de wnt/beta- catenina.

Country Status (32)

Country Link
US (5) US9533976B2 (es)
EP (2) EP3456325A3 (es)
JP (2) JP6401189B2 (es)
KR (1) KR102252567B1 (es)
CN (1) CN105188696A (es)
AU (2) AU2014218720B2 (es)
BR (1) BR112015020391B1 (es)
CA (1) CA2901671C (es)
CL (2) CL2015002363A1 (es)
CY (1) CY1122751T1 (es)
DK (1) DK2968249T3 (es)
ES (1) ES2709824T3 (es)
HR (1) HRP20190142T1 (es)
HU (1) HUE042001T2 (es)
IL (1) IL240628B (es)
LT (1) LT2968249T (es)
MA (1) MA38421A1 (es)
ME (1) ME03296B (es)
MX (1) MX368663B (es)
MY (1) MY176004A (es)
PE (1) PE20151721A1 (es)
PH (1) PH12015501847A1 (es)
PL (1) PL2968249T3 (es)
PT (1) PT2968249T (es)
RS (1) RS58432B1 (es)
RU (2) RU2019104082A (es)
SG (2) SG11201506592SA (es)
SI (1) SI2968249T1 (es)
SM (1) SMT201900059T1 (es)
TR (1) TR201901496T4 (es)
WO (1) WO2014130869A1 (es)
ZA (1) ZA201506438B (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10259817B2 (en) 2015-06-23 2019-04-16 Eisai R&D Management Co., Ltd. Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US12226409B2 (en) 2017-05-16 2025-02-18 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20151425T1 (hr) 2009-08-10 2016-01-29 Samumed, Llc Inhibitori indazola wnt signalnog puta i njihove terapeutske uporabe
EP3915367A1 (en) 2010-08-18 2021-12-01 BioSplice Therapeutics, Inc. Diketones and hydroxyketones as catenin signaling pathway activators
JP6401189B2 (ja) * 2013-02-22 2018-10-03 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔ／β−カテニンシグナル伝達経路活性化剤としてのγ−ジケトン
HRP20192161T1 (hr) 2014-08-20 2020-02-21 Samumed, Llc Gama-diketoni za liječenje i prevenciju starenja kože i bora
CN104311544A (zh) * 2014-09-22 2015-01-28 湖南华腾制药有限公司 一种苯并恶唑衍生物的制备方法
CN104292179A (zh) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 一种2-氯苯并[d]恶唑-5-甲醛的制备方法
CN109678687B (zh) * 2018-12-11 2022-02-11 沾化大荣化工科技有限公司 一种邻羟基苯乙酮类化合物的高效制备方法
US12398126B2 (en) * 2019-06-06 2025-08-26 Fermenta Biotech Limited Process to synthesize 5-(3pyridyl)-2,2′-bithiophene(sensitizer)
CN111632147A (zh) * 2020-06-07 2020-09-08 重庆医科大学 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用
EP4173675A1 (en) * 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
CN116808027B (zh) * 2023-05-30 2025-08-29 重庆医科大学附属第一医院 化合物或其盐在制备抑制wnt7a基因活性的制剂中的应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3040054A (en) * 1960-08-03 1962-06-19 Olin Mathieson 2, 2'-(1, 4-diaminotetramethylene) bis(4-thiazolecarboxylic acid), salts and process
US3855675A (en) 1971-05-25 1974-12-24 Squibb & Sons Inc 1-(2-furanylmethyl)-1h-pyrazolo(3,4-b)pyridine-5-methanones
US4014889A (en) 1972-12-20 1977-03-29 Bayer Aktiengesellschaft Process for preparing ketones
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
DE3331692A1 (de) 1983-09-02 1985-03-28 Basf Ag, 6700 Ludwigshafen 3-phenyl-4-methoxycarbonylpyrazole, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
EP0230110A1 (en) 1985-11-30 1987-07-29 FISONS plc Pharmacologically active pyrrole and pyrazole derivatives
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP0290442A4 (en) 1986-11-19 1990-07-03 Chemex Pharmaceuticals Inc MEDICINAL PREPARATIONS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS.
FR2613360B1 (fr) 1987-04-03 1989-06-09 Oreal Nouveaux derives aromatiques d'acide butyrique, leur procede de preparation et leur utilisation en medecine humaine et veterinaire ainsi qu'en cosmetique
NZ227287A (en) 1987-12-21 1992-01-29 Merck & Co Inc 2,5-diaryl tetrahydrofurans and medicaments
AU626881B2 (en) 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
EP0365089A3 (en) 1988-10-18 1991-06-05 Merck & Co. Inc. 2-aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl) tetrahydrothiophen and analogs
DK0429570T3 (da) 1989-03-28 1998-04-27 Genetics Inst Osteoinducerende præparater
DK0454204T3 (da) 1990-04-27 1995-08-28 Duphar Int Res Fremgangsmåde til fotokemisk isomerisering af organiske forbindelser og indflydelse herpå af en fotosensibilisator
DE4104931A1 (de) 1991-02-18 1992-08-20 Hoechst Ag Verfahren zur herstellung substituierter indene
JPH05170764A (ja) 1991-12-24 1993-07-09 Sumitomo Pharmaceut Co Ltd 新規なヒドロキシカルコン誘導体
GB9203806D0 (en) 1992-02-21 1992-04-08 Unilever Plc Sunscreen agents
DK57892D0 (da) 1992-05-01 1992-05-01 Nkt Res Center As Fremgangsmaade til fremstilling af 1,4-bis-aryl-butan-1,4-dioner og poly(arylen-butan-1,4-dioner)
ES2157345T3 (es) 1994-10-07 2001-08-16 Meiji Seika Co Compuestos de gamma-dicetona con actividad inhibidora contra la agregacion de plaquetas.
WO1996021665A1 (en) * 1995-01-13 1996-07-18 Board Of Regents, The University Of Texas System Turcasarins, novel expanded porphyrins, and uses thereof
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
US5585118A (en) 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
US5668165A (en) 1995-06-07 1997-09-16 Scriptgen Pharmaceuticals, Inc. Small molecule inhibition of RNA/ligand binding
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
AU719396B2 (en) 1996-02-19 2000-05-11 Japan Tobacco Inc. Therapeutic agent for diabetes
DE69724472T2 (de) 1996-06-03 2004-06-17 Purdue Research Foundation, West Lafayette Selenophen-antitumormittel
US6620804B2 (en) * 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
TR200100426T2 (tr) 1998-08-11 2001-06-21 Nihon Bayer Agrochem K.K. Nematisit pirazoller
EP1127054A4 (en) 1998-10-29 2006-11-02 Bristol Myers Squibb Co INHIBITORS OF IMPDH ENZYME
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
EP1196384A4 (en) 1999-06-25 2002-10-23 Merck & Co Inc 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS
EP1067195B1 (de) 1999-07-09 2006-09-20 Forschungszentrum Jülich Gmbh Verfahren zur Reduktion von Ketogruppen enthaltende Verbindungen
ATE307120T1 (de) 1999-07-13 2005-11-15 Lonza Ag Verfahren zur herstellung von 2-amino-4(4- fluorphenyl)-6-alkylpyrimidin-5-carbonsäureeste
DE60019505T2 (de) 1999-08-06 2005-09-15 Ciba Speciality Chemicals Holding Inc. Mikrobizide Wirksubstanzen
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
EP1224189B1 (en) 1999-10-07 2006-01-25 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
US6268375B1 (en) 1999-12-29 2001-07-31 Research Triangle Institute 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2001294581A (ja) 2000-04-12 2001-10-23 Nippon Bayer Agrochem Co Ltd イソチアゾール誘導体
US6794362B1 (en) 2000-05-30 2004-09-21 Connective Tissue Imagineering Llc Asparagine containing elastin peptide analogs
PT1300398E (pt) 2000-07-05 2006-07-31 Astellas Pharma Inc Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta
DE10059749A1 (de) 2000-12-01 2002-06-20 Henkel Kgaa Fixierung von Wirkstoffen an fasrigen Materialien
DE60229114D1 (en) 2001-03-02 2008-11-13 Axys Pharm Inc Cathepsincystein-proteasehemmer
DE60223790D1 (de) 2001-03-29 2008-01-10 Vertex Pharma Hemmer von c-jun-terminal kinase (jnk) und andere protein kinase
CA2439593C (en) 2001-04-05 2010-02-09 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
CA2444882A1 (en) 2001-04-30 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
WO2003016266A1 (fr) 2001-08-16 2003-02-27 Japan Tobacco Inc. Composes $g(b)-cetoamides et leur utilisation medicinale
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
CN1599602A (zh) 2001-10-11 2005-03-23 钟渊化学工业株式会社 过氧化物酶体增殖剂应答性受体配体剂及其制备方法
EP1463715A1 (en) * 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
CN1155590C (zh) 2002-04-12 2004-06-30 中国药科大学 具有抗肿瘤活性的色酮类化合物及其开环产物与制备方法
EP1534680B1 (en) 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Prenylation inhibitors and methods of their synthesis and use
US20040266732A1 (en) 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
FR2849598B1 (fr) 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US20040224003A1 (en) 2003-02-07 2004-11-11 Schultz Robert K. Drug formulations for coating medical devices
JP2006523707A (ja) 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
CN102875441A (zh) 2003-07-17 2013-01-16 普莱希科公司 Ppar活性化合物
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20060276536A1 (en) 2004-02-12 2006-12-07 Vander Jagt David L Cancer treatment using curcumin derivatives
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
US20070185152A1 (en) 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
JP5002452B2 (ja) 2004-05-06 2012-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換エナミノン類、それらの誘導体およびそれらの使用
CN1964950A (zh) 2004-06-04 2007-05-16 安斯泰来制药有限公司 丙烷－1,3－二酮衍生物或其盐
DE102004029309A1 (de) 2004-06-17 2005-12-29 Bayer Cropscience Gmbh Pyridinylisoxazole und ihre Verwendung als Herbizide
EP1763345A2 (en) 2004-06-18 2007-03-21 GPC Biotech Inc. Kinase inhibitors for treating cancers
EP1786415A4 (en) 2004-08-16 2010-01-20 Verva Pharmaceuticals Pty METABOLISM MODULATION AGENTS AND USES THEREOF
US7351745B2 (en) 2004-12-22 2008-04-01 Avon Products, Inc Compositions and methods of their use for improving the condition and appearance of skin
FR2880802B1 (fr) 2005-01-14 2008-12-19 Sederma Soc Par Actions Simpli Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
EP1861161A4 (en) 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
AU2006211159A1 (en) * 2005-02-01 2006-08-10 Wyeth Amino-pyridines as inhibitors of beta-secretase
DK1864976T3 (da) 2005-03-31 2012-10-22 Astellas Pharma Inc Propan-1,3-dion-derivat eller salt deraf
JP5050206B2 (ja) * 2005-06-27 2012-10-17 国立大学法人東北大学 ビス（アリールメチリデン）アセトン化合物、抗癌剤、発癌予防剤、Ｋｉ−Ｒａｓ、ＥｒｂＢ２、ｃ−Ｍｙｃ及びＣｙｃｌｉｎＤ１の発現抑制剤、β−カテニン分解剤並びにｐ５３の発現増強剤
DE102005031580A1 (de) 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
CN101365446B (zh) 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
EP1954274B8 (en) 2005-11-10 2011-01-12 ChemoCentryx, Inc. Substituted quinolones and methods of use
WO2007103584A2 (en) 2006-03-09 2007-09-13 Nanovir, Llc Polyamides for treating human papilloma virus
KR20080109918A (ko) 2006-04-11 2008-12-17 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
JP2008007428A (ja) 2006-06-27 2008-01-17 Showa Denko Kk 皮膚外用シワ防止剤
JPWO2008020625A1 (ja) * 2006-08-17 2010-01-07 国立大学法人金沢大学 ジベンゾイルメタン系化合物とそれを有効成分とする医薬組成物
WO2008026318A1 (fr) 2006-08-30 2008-03-06 Kabushiki Kaisha Yakult Honsha Agent anti-ride
US7875603B2 (en) 2006-09-21 2011-01-25 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
JP5207341B2 (ja) 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US7799954B2 (en) * 2006-11-17 2010-09-21 Abraxis Bioscience, Llc Dicarbonyl derivatives and methods of use
JP5231829B2 (ja) 2007-02-15 2013-07-10 石原産業株式会社 ピリジル−トリアゾロピリミジン誘導体又はその塩、それらを含有する有害生物防除剤並びにそれらの製造方法
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
JP5309318B2 (ja) 2007-03-09 2013-10-09 国立大学法人 岡山大学 エステル、カルボン酸及びアミドの製造方法
WO2008129255A1 (en) 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
KR101404398B1 (ko) 2007-06-20 2014-06-09 (주)뉴트리 주름개선 화장료 조성물
BRPI0820327A2 (pt) 2007-11-02 2020-10-06 Novartis Ag moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
MX2010004982A (es) 2007-11-05 2010-08-16 Novartis Ag Metodos y composiciones para medir la activacion de wnt y para el tratamiento de canceres relacionados con wnt.
WO2009071997A2 (en) 2007-12-06 2009-06-11 Centre National De La Recherche Scientifique (C.N.R.S.) Iron and copper catalytic systems for cross-coupling reactions
JP2009179619A (ja) 2008-02-01 2009-08-13 Toyo Ink Mfg Co Ltd 新規オキシムエステル化合物およびそれを含んでなるラジカル重合開始剤および重合性組成物
CN102099005A (zh) 2008-02-27 2011-06-15 先灵-普劳健康护理产品公司 含有阿伏苯宗的防晒组合物增强的光稳定性
KR101626136B1 (ko) 2008-04-14 2016-06-03 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 플렉스트린 상동 도메인의 소분자 억제제 및 이의 사용방법
KR101538822B1 (ko) 2008-05-08 2015-07-22 노바 사우쓰이스턴 유니버시티 혈관 내피 성장 인자 수용체에 대한 특이적 억제제
ES2622148T3 (es) 2008-11-05 2017-07-05 University Of Southern California Moduladores de Moléculas Pequeñas de Regulación Epigenética y sus Aplicaciones Terapéuticas
WO2010075551A1 (en) * 2008-12-24 2010-07-01 Massachusetts Institute Of Technology Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
JP5246715B2 (ja) 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011009826A2 (en) 2009-07-21 2011-01-27 ADAMED Sp.z o.o. Novel chalcone derivatives with cytotoxic activity
EP3915367A1 (en) 2010-08-18 2021-12-01 BioSplice Therapeutics, Inc. Diketones and hydroxyketones as catenin signaling pathway activators
KR101784940B1 (ko) 2010-08-31 2017-10-12 (주)아모레퍼시픽 피부 탄력 개선용 화장료 조성물
US9249087B2 (en) 2011-02-01 2016-02-02 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
KR101285259B1 (ko) 2011-08-04 2013-07-11 (주)케어젠 Ｗｎｔ 계열 유래 펩타이드 및 이의 용도
US8871748B2 (en) 2011-09-07 2014-10-28 Island Kinetics Inc. Retinal cyclodextrin acetals and hemiacetals for treating skin complexion disorder
US9668691B2 (en) 2011-09-22 2017-06-06 Lvmh Recherche Method to measure skin elasticity and firmness
ES2958619T3 (es) 2012-01-30 2024-02-12 Univ Gent Compuestos anti-invasivos
US20130302381A1 (en) 2012-05-09 2013-11-14 Cook Medical Technologies Llc Implantable Medical Devices Including a Water-Insoluble Therapeutic Agent
US8865700B2 (en) 2012-12-20 2014-10-21 Avon Products, Inc. Collagen stimulators and their use in the treatment of skin
MX362355B (es) 2013-02-22 2019-01-14 H Lundbeck As Proceso de fabricacion de vortioxetina.
JP6401189B2 (ja) 2013-02-22 2018-10-03 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔ／β−カテニンシグナル伝達経路活性化剤としてのγ−ジケトン
PE20151764A1 (es) 2013-02-22 2015-12-03 Pfizer Derivados de pirrolo[2,3-d]pirimidina
EP3556400A1 (en) 2013-02-22 2019-10-23 AbbVie Stemcentrx LLC Method of making antidll3-antibody pbd conjugates
HRP20192161T1 (hr) 2014-08-20 2020-02-21 Samumed, Llc Gama-diketoni za liječenje i prevenciju starenja kože i bora

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US10259817B2 (en) 2015-06-23 2019-04-16 Eisai R&D Management Co., Ltd. Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US12226409B2 (en) 2017-05-16 2025-02-18 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Also Published As

Publication number Publication date
RU2680716C2 (ru) 2019-02-26
PE20151721A1 (es) 2015-12-07
EP2968249B1 (en) 2018-11-14
CA2901671C (en) 2021-07-13
AU2014218720A1 (en) 2015-09-03
AU2014218720B2 (en) 2018-09-27
US20200223834A1 (en) 2020-07-16
LT2968249T (lt) 2019-03-12
BR112015020391B1 (pt) 2022-07-26
PH12015501847B1 (en) 2015-12-07
HUE042001T2 (hu) 2019-06-28
BR112015020391A2 (pt) 2017-07-18
RS58432B1 (sr) 2019-04-30
TR201901496T4 (tr) 2019-02-21
RU2015140118A (ru) 2017-03-28
EP3456325A2 (en) 2019-03-20
PL2968249T3 (pl) 2019-06-28
IL240628A0 (en) 2015-10-29
SI2968249T1 (sl) 2019-04-30
US20190055227A1 (en) 2019-02-21
US9533976B2 (en) 2017-01-03
JP2019031496A (ja) 2019-02-28
MX368663B (es) 2019-10-10
HK1214953A1 (en) 2016-08-12
SMT201900059T1 (it) 2019-02-28
ES2709824T3 (es) 2019-04-17
US11673885B2 (en) 2023-06-13
US20170260176A1 (en) 2017-09-14
KR102252567B1 (ko) 2021-05-17
US9951053B2 (en) 2018-04-24
CY1122751T1 (el) 2021-03-12
US20230053726A1 (en) 2023-02-23
DK2968249T3 (en) 2019-03-04
PH12015501847A1 (en) 2015-12-07
JP6401189B2 (ja) 2018-10-03
ME03296B (me) 2019-07-20
WO2014130869A1 (en) 2014-08-28
ZA201506438B (en) 2023-01-25
AU2018275021A1 (en) 2019-01-03
EP2968249A4 (en) 2016-07-06
IL240628B (en) 2019-12-31
CN105188696A (zh) 2015-12-23
US10457672B2 (en) 2019-10-29
MA38421A1 (fr) 2017-03-31
US11034682B2 (en) 2021-06-15
CL2015002363A1 (es) 2016-03-11
EP3456325A3 (en) 2019-05-22
CA2901671A1 (en) 2014-08-28
RU2019104082A (ru) 2019-04-10
EP2968249A1 (en) 2016-01-20
JP2016514100A (ja) 2016-05-19
US20140243349A1 (en) 2014-08-28
SG11201506592SA (en) 2015-09-29
KR20150119942A (ko) 2015-10-26
HRP20190142T1 (hr) 2019-03-22
SG10201606032VA (en) 2016-09-29
PT2968249T (pt) 2019-02-06
MX2015010948A (es) 2016-05-05
MY176004A (en) 2020-07-21

Similar Documents

Publication Publication Date Title
CL2016001367A1 (es) Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015).
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
GT201300153A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diamina
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
CL2015002239A1 (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
MX2017016997A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2015001916A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
UY35467A (es) Compuestos orgánicos
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34781A (es) Moduladores de la via del complemento y usos de los mismos
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
MX2017007377A (es) Compuestos organicos.
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel